Clinical trials: Cancer Patient, open to volunteers
Diffuse Large B-Cell Lymphoma
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL)…
- Trial name
- DEL-MRD-CHID (NCT07507318)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Rong Tao
Breast Cancer
Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
cN3c breast cancer with ipsilateral supraclavicular (SCV) lymph nodal (SCLN) metastasis is known to have a dismal prognosis. Currently, the combined-modality therapy consisting of primary systemic therapy (PST), subsequent local…
- Trial name
- NCT06404697
- Testing
- Boost irradiation
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ruijin Hospital
Acupuncture, Taste Disorders
Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy
This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing…
- Conditions
- Acupuncture, Taste Disorders, Dysgeusia, Chemotherapy
- Trial name
- OralAcu (NCT02304913)
- Testing
- Hypoglossal acupuncture, Dietary recommendations
- Where
- 3 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Universität Duisburg-Essen
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting…
- Conditions
- B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05365659
- Testing
- IKS03
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Iksuda Therapeutics Ltd.
Colorectal Cancer, CRC
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06445062
- Testing
- RMC-6236, mFOLFOX6 regimen, bevacizumab
- Where
- 32 sites in United States
- Volunteers
- 1,130 people
- Sponsor
- Revolution Medicines, Inc.
Postoperative Delirium (POD), Prostate Cancer
Preoperative Breathing Exercise Training and Postoperative Delirium After Robotic Radical Prostatectomy
Postoperative delirium is an acute and fluctuating disturbance in attention, awareness, and thinking that may occur after major surgery.
- Trial name
- NCT07766603
- Testing
- Preoperative Deep Breathing Exercise Training
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- ALİ DEMİRTAŞ
Abdominal Sepsis
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including…
- Trial name
- 18F-FDG PET/CT (NCT07127627)
- Testing
- PET/CT
- Volunteers
- 79 people
- Sponsor
- Assiut University
DMG, DIPG
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for Diffuse Midline Glioma (DMG), an aggressive brain tumor with a very poor prognosis - an average one-year overall survival.
- Trial name
- LIFT (NCT07796061)
- Testing
- TAA-T Cell, BBB Disruption
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's National Research Institute
Cutaneous Metastasis, Cutaneous Malignant Mixed Tumor
The Effect of Reduced Bleomycin in Electrochemotherapy Treatment
The objective of this trial is to determine if reducing the chemotherapy dose in electrochemotherapy is equally effective as using the standard dose for treating various types of skin tumors.
- Conditions
- Cutaneous Metastasis, Cutaneous Malignant Mixed Tumor, Bleomycin Adverse Reaction, Electrochemotherapy
- Trial name
- BLESS (NCT06647342)
- Testing
- Bleomycin
- Where
- 2 sites in Denmark
- Volunteers
- 55 people
- Sponsor
- Julie Gehl
Breast Cancer
SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology
Prospective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients.
- Trial name
- SAHARA-04 (NCT06053086)
- Testing
- Treatment ETHOS radiotherapy, Conventional IMRT
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
Brief Summary This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in…
- Trial name
- CS (NCT07675876)
- Testing
- Cromolyn Sodium
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Carcinex Inc
Melanoma, Stage II
Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous Melanoma.
Exploring the effect of supplementation with daily addition of prebiotic dried chicory root (WholeFiberTM) for 6 weeks on fecal SCFA levels, gut microbial composition and immune cell composition in minimal stage II A melanoma…
- Trial name
- MELFIB (NCT07206017)
- Testing
- prebiotic dried chicory root (WholeFiber)
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
T-cell Lymphoma, T-cell Leukemia
CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma.
- Trial name
- NCT03829540
- Testing
- CD4CAR
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Huda Salman
SCLC, Recurrent
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
This is a multicenter, open-label, single-arm phase 2 study evaluating the efficacy and safety of ivonescimab combined with paclitaxel polymeric micelles in adults with recurrent or refractory small cell lung cancer after failure…
- Trial name
- NCT07819591
- Testing
- Paclitaxel Polymeric Micelles, Ivonescimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shaodong Hong
Head and Neck Neoplasms, Radiodermatitis
Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer
This study evaluates a topical 2% Boswellia serrata (Indian olibanum) gum-resin cream for the prevention of acute radiation-induced dermatitis in patients with head and neck cancer undergoing radiotherapy.
- Trial name
- NCT07778290
- Testing
- Boswellia serrata 2% topical cream
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Youssef Hashem Hafez
Neuroendocrine (NE) Tumors, Oral Anti-Tumor Drugs
Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program
In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home.
- Conditions
- Neuroendocrine (NE) Tumors, Oral Anti-Tumor Drugs, Therapeutic Education Program
- Trial name
- ETP-NET (NCT07258810)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Advanced Solid Tumor
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
- Trial name
- NCT06257680
- Testing
- ReT01 ACT
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Xunsheng Biomedical Research Co., Ltd.
Pancreatic Cancer, Pancreatic Neoplasms
Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer
The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related…
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Periampullary Carcinoma, Pancreatic Surgery
- Trial name
- POWR-PaC (NCT07772258)
- Testing
- Corsano CardioWatch, Prehab4Cancer Programme
- Volunteers
- 120 people
- Sponsor
- Manchester University NHS Foundation Trust
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.